Praluent (Alirocumab) Missed-Dose Protocol: What Women Need to Know

What Is Alirocumab and How Does It Work?

Alirocumab is a fully human monoclonal antibody that targets PCSK9, a protein your liver makes to destroy LDL receptors. By blocking PCSK9, alirocumab keeps those receptors working, so your liver pulls more LDL cholesterol out of circulation. The result is a dramatic, sustained LDL reduction that statins alone rarely match.

Sold as Praluent and co-developed by Regeneron and Sanofi, alirocumab is approved by the FDA for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on maximally tolerated statin therapy.

The PCSK9 Pathway in Women

PCSK9 biology is not sex-neutral. Estrogen suppresses PCSK9 expression, which is part of why premenopausal women generally carry lower LDL than age-matched men. After menopause, estrogen loss removes that brake: PCSK9 concentrations rise significantly in postmenopausal women compared to premenopausal controls, contributing to the well-documented postmenopausal LDL surge. This means PCSK9 inhibition may carry particular biological relevance for women in the menopausal transition and beyond.

During the reproductive years, LDL also fluctuates across the menstrual cycle, with levels tending to peak in the luteal phase and dip mid-cycle. This variation is modest clinically but worth noting when you interpret a single fasting lipid panel.

ODYSSEY OUTCOMES: The Key Trial

The landmark evidence base for alirocumab in high-risk patients is the ODYSSEY OUTCOMES trial, published in the New England Journal of Medicine in 2018. The trial enrolled 18,924 patients with recent acute coronary syndrome (ACS) on high-intensity statin therapy and randomized them to alirocumab 75 mg every two weeks (titrated to 150 mg if needed) or placebo. Alirocumab produced a 15% relative reduction in major adverse cardiovascular events (MACE), including a significant reduction in all-cause mortality in the prespecified subgroup with baseline LDL at or above 100 mg/dL.

Women represented approximately 25% of ODYSSEY OUTCOMES participants. The sex-specific subgroup analysis showed directionally consistent benefit, though the trial was not powered to detect a statistically significant difference in women independently. This is an evidence gap worth naming plainly: most PCSK9 trial populations skew male, and direct cardiovascular outcome data in women remains thinner than we would like.

The Missed-Dose Protocol: Step by Step

Missing an injection does not erase your cardiovascular protection, but the timing of your catch-up dose matters because PCSK9 rebounds quickly once the antibody clears.

The Core Rule

Alirocumab's FDA-approved prescribing information states:

• If you miss a dose and the next scheduled dose is more than 7 days away, inject the missed dose as soon as you remember.
• If the next scheduled dose is within 7 days, skip the missed dose entirely and resume your regular schedule.
• Never inject two doses at once.

After a catch-up injection, your new dosing schedule restarts from that date.

Why the 7-Day Rule Exists

Alirocumab has a half-life of approximately 17 to 20 days, so LDL suppression does not collapse overnight after a single missed dose. However, PCSK9 rebound becomes clinically meaningful beyond about one week of the missed window, particularly in women with familial hypercholesterolemia or very high baseline LDL who depend on near-complete PCSK9 blockade. Catching up within seven days keeps trough alirocumab concentrations above the threshold for adequate receptor occupancy.

What to Do If You Missed More Than One Dose

The prescribing label addresses a single missed dose. If you have missed two or more consecutive doses, contact your prescriber before self-administering. A repeat lipid panel may be warranted to assess LDL rebound, and your provider may consider a temporary dose adjustment if you are on the 75 mg regimen and LDL has risen above goal.

Injection Technique After a Gap

If several weeks have passed since your last injection, inspect the solution before use. Praluent should be clear to slightly opalescent, colorless to pale yellow, and free of visible particles. Do not use a prefilled pen or syringe that has been left at room temperature for more than 30 minutes or that shows cloudiness or discoloration. Rotate your injection site, avoiding any area that is tender, bruised, or scarred from a prior injection.

How Praluent Is Dosed Across Life Stages

Reproductive Years (Ages Roughly 18 to 45)

Women in their reproductive years are far less likely to have established ASCVD but may carry HeFH, an autosomal dominant condition affecting approximately 1 in 250 people in the general population. HeFH is often first identified in young women during routine cholesterol screening or prenatal workup, when LDL values that appeared manageable on statin therapy may spike dramatically during pregnancy.

The standard starting dose is 75 mg every two weeks. If LDL response is insufficient at 8 to 12 weeks, your prescriber may increase to 150 mg every two weeks. A monthly 300 mg dose is an alternative for women who prefer less frequent injections.

For women who are trying to conceive or who are not using reliable contraception, alirocumab must be discussed carefully with your prescriber before starting. See the Pregnancy and Lactation section below.

Perimenopause (Ages Roughly 45 to 55)

The menopausal transition is a critical cardiovascular inflection point. LDL cholesterol rises by an average of 10 to 14 mg/dL in the two years surrounding the final menstrual period, independent of age or weight gain. For women with HeFH or existing ASCVD who were previously stable on statin therapy, this hormonal shift can push LDL above goal and trigger a dose escalation or the addition of alirocumab.

Vasomotor symptoms can also complicate injection adherence. Hot flashes and night sweats disrupt sleep and routine, and an irregular schedule makes missed doses more likely. Building your injection day into a fixed ritual, such as the same evening you pick up your weekly prescription refills, reduces the chance of a gap.

Postmenopause

This is the life stage where alirocumab prescriptions are most commonly initiated in women. Postmenopausal women with established ASCVD who cannot achieve LDL goals below 70 mg/dL on high-intensity statins are the clearest candidates. The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction supports adding a PCSK9 inhibitor for very high-risk patients whose LDL remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe.

Subcutaneous absorption does not change meaningfully with age, though postmenopausal women with lower body mass may find the thigh or abdomen preferable to the upper arm for more predictable absorption. Skin atrophy from aging can make the pen auto-injector feel more intense; pressing the pen firmly against the skin before activating it improves contact and reduces stinging.

Praluent and Female-Relevant Conditions

Familial Hypercholesterolemia in Women

HeFH is the most common serious genetic lipid disorder, and it carries sex-specific implications. Young women with untreated HeFH lose the cardiovascular protection that estrogen provides premenopausal women in general, meaning their ASCVD risk more closely resembles that of age-matched men with HeFH. The European Atherosclerosis Society consensus recommends LDL targets below 100 mg/dL for HeFH adults without other risk factors, and below 70 mg/dL for those with established ASCVD. Alirocumab often becomes necessary when these targets are unreachable on statins alone.

PCOS and Metabolic Dyslipidemia

Polycystic ovary syndrome (PCOS) is associated with a dyslipidemia pattern of elevated triglycerides, low HDL, and, in a subset, elevated LDL or small dense LDL particles. Women with PCOS have approximately two-fold higher odds of dyslipidemia than controls in large meta-analyses. While alirocumab targets LDL specifically and does not address the triglyceride component of PCOS dyslipidemia, it is relevant for the subset of women with PCOS who also carry HeFH or who develop frank LDL elevation.

Thyroid Disease

Hypothyroidism raises LDL by reducing LDL receptor activity, a mechanism that overlaps with but is distinct from PCSK9 upregulation. Women are five to eight times more likely than men to develop autoimmune hypothyroidism. Before escalating lipid therapy in any woman with persistently elevated LDL, ensure TSH is checked; correcting hypothyroidism may reduce LDL sufficiently to eliminate the need for a PCSK9 inhibitor.

Postpartum Dyslipidemia

Cholesterol normalizes gradually after delivery, typically by 6 to 8 weeks postpartum. Women who had gestational dyslipidemia or who are newly diagnosed with HeFH postpartum should have a fasting lipid panel at their 6-week visit. Statin therapy is the first-line option once breastfeeding concludes, with PCSK9 inhibitors reserved for statin-intolerant or high-LDL cases.

Pregnancy, Lactation, and Contraception

Alirocumab is contraindicated during pregnancy. If you are pregnant or planning to become pregnant, discuss stopping this medication with your prescriber before conception if possible.

Pregnancy Safety Data

Alirocumab falls under the FDA's post-2015 labeling system, which replaced the old A/B/C/D/X letter categories. The current prescribing information states that there are no adequate and well-controlled studies of alirocumab in pregnant women. Animal reproductive studies showed no direct fetal harm at doses approximating human exposure, but IgG antibodies cross the placenta via the neonatal Fc receptor, particularly in the second and third trimesters. The potential for fetal LDL suppression during a period of active neurological development is a theoretical concern that has not been resolved in human data.

Because LDL cholesterol is a substrate for fetal steroid hormone synthesis, significant fetal LDL suppression carries an uncharacterized developmental risk. Clinicians generally recommend discontinuing alirocumab at least one month before a planned conception attempt, given its 17 to 20 day half-life, to allow near-complete clearance before implantation.

Statins are also contraindicated in pregnancy, which creates a management gap for pregnant women with HeFH. ACOG practice guidance supports LDL apheresis as the most evidence-based option for managing severe HeFH during pregnancy in women who cannot reach acceptable LDL levels through diet alone. Bile acid sequestrants such as cholestyramine are sometimes used as a lower-risk option, given their minimal systemic absorption.

Lactation

No human data on alirocumab transfer into breast milk exist. IgG antibodies are present in colostrum and mature breast milk at low levels, but oral bioavailability of large monoclonal antibodies in a nursing infant is considered very low due to gastrointestinal proteolysis. Despite this pharmacological reassurance, the absence of human lactation data means most guidelines advise avoiding alirocumab while breastfeeding. The decision should be individualized with your prescriber, weighing maternal cardiovascular risk against the unknown infant exposure.

Contraception Requirements

Women of reproductive potential taking alirocumab should use reliable contraception. Given the theoretical fetal risk from LDL suppression and the IgG placental transfer in later pregnancy, an unintended pregnancy on alirocumab warrants prompt contact with your obstetric provider and a shared decision-making conversation about continuing or stopping the medication. No specific contraceptive method is mandated by the prescribing information, but long-acting reversible contraception (LARC) offers the highest real-world efficacy and eliminates user-dependent failure.

Who Is a Good Candidate, and Who Is Not

Most Likely to Benefit

The following framework synthesizes FDA labeling, ACC/AHA 2022 guidelines, and the ODYSSEY OUTCOMES data to identify women most likely to gain cardiovascular benefit from alirocumab:

| Profile | Life Stage | LDL Target | Alirocumab Fits? | |---|---|---|---| | HeFH, no ASCVD, statin-intolerant | Reproductive, peri, postmeno | <100 mg/dL | Yes | | HeFH plus established ASCVD | Any | <55 mg/dL | Yes, high priority | | Post-ACS, LDL ≥70 on max statin | Peri/postmeno | <70 mg/dL | Yes, ODYSSEY OUTCOMES population | | Statin-naive, elevated LDL, no ASCVD | Reproductive | LDL-dependent | No, not first line | | Pregnant, any indication | Pregnancy | N/A | Contraindicated | | Breastfeeding, HeFH | Postpartum | LDL-dependent | Avoid; use bile acid sequestrant or defer | | PCOS, elevated triglycerides only | Reproductive | Trig-focused | No, alirocumab targets LDL not TG |

Cautions and Relative Contraindications

Women with a prior serious hypersensitivity reaction to alirocumab or any excipient should not use it. Injection-site reactions are the most common adverse effect, reported in approximately 7% of alirocumab-treated patients versus 5% on placebo in pooled phase 3 data. Neurocognitive complaints, including confusion and memory impairment, were reported at a low rate in clinical trials and have not been confirmed as a causal adverse effect in large randomized data; however, discuss any new cognitive symptoms with your prescriber.

Storing Praluent and Practical Injection Tips for Women

Praluent prefilled pens and syringes are stored in the refrigerator at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). If refrigeration is temporarily unavailable, the product may be stored at room temperature below 77 degrees Fahrenheit for up to 30 days, after which it must be discarded.

Practical notes for women:

• Menstrual cycle timing: No evidence supports timing injections to a specific cycle phase, but some women find it easier to anchor injections to a calendar day rather than a cycle day for consistency.
• Insulin pen users: If you also inject insulin or other biologics, alternate injection zones to prevent lipohypertrophy at any single site.
• Travel: Carry Praluent in an insulated cooler bag during flights; declare it at security. TSA allows injectable medications with documentation.
• Auto-injector technique: Press the pen fully against the skin, wait for the first click to start the injection, and hold for the second click before removing. This full contact step is where many missed or incomplete doses occur.

Monitoring While on Alirocumab

Your prescriber will typically check a fasting lipid panel four to twelve weeks after starting or changing your alirocumab dose to confirm LDL response. Ongoing monitoring frequency depends on your ASCVD risk and your stability on the regimen, but annual lipid panels are standard once you reach goal.

For women in the menopausal transition, plan a lipid check at each annual menopause visit because rising LDL during perimenopause may shift your risk category or LDL target even while you remain on the same alirocumab dose.

If you are taking hormone therapy (HT) for menopausal symptoms concurrently, be aware that oral estrogen raises triglycerides and may modestly affect LDL as well. Transdermal estrogen has a more neutral lipid effect. The Menopause Society 2023 position statement notes that the route of estrogen administration influences lipid and coagulation parameters, which is relevant when interpreting lipid panels on combined HT and alirocumab therapy.